Pharma Focus Asia
KP - Choose our fully recyclable blister films

A Breakthrough Therapy Developed for Investigational Prenatal Treatment ER-004 a Rare Genetic Condition

ER-004, a breakthrough therapy for the prenatal treatment of XLHED, a life-threatening rare genetic condition was developed by EspeRare.

Breakthrough Designation was obtained by the promising results from three XLHED subjects with a course of ER-004 intra-amniotic injections during the third trimester of pregnancy.Hence results obtained from this prenatal treatment have a profound and life-changing effect on these infants.

Rare diseases such as XLHED often don't receive much attention and research investments that patients and their families deserve.This breakthrough therapy approach has the potential to fundamentally change the lives of patients and may also pave the way for other prenatal treatments to correct genetic diseases before birth.

US FDA grants Breakthrough Therapy Designation for Investigational Prenatal Treatment ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)protein replacement therapy for the treatment for the prenatal treatment of XLHED, a life-threatening rare genetic condition.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023
MasterControl - 6 Essential Features in an eQMS